For both AMD and RP, currently available therapies normally only aim to slow down the death of photoreceptors, by providing nutritional supplements (Krishnadev et al., 2010) or through anti-vascular endothelial growth factor (anti-VEGF) injections (Ba et al., 2015) and lasers (Virgili et al., 2015), with limited available treatments for stopping the progression of the diseases or restoring vision. Here, VEGFA is linked to retinitis pigmentosa 1.